Cover Image
市場調查報告書

醫藥品相關應用程式比較分析:製藥企業的行動應用程式有效利用方法

Pharma App Benchmarking 2014 - How Pharma companies make use of mobile apps

出版商 research2guidance 商品編碼 317344
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品相關應用程式比較分析:製藥企業的行動應用程式有效利用方法 Pharma App Benchmarking 2014 - How Pharma companies make use of mobile apps
出版日期: 2014年10月27日 內容資訊: 英文
簡介

本報告提供全球各國的11家主要製藥企業開發、提供的Android/iOS設備應用比較分析、應用程式在製藥產業的活用狀況,及企業層級的應用程式開發、活用狀況比較、各應用程式的性能、實際成果(專家/一般客戶的下載數等,共725種)的資訊,為您概述為以下內容。

第1章 分析範圍

第2章 關於research2guidance

第3章 管理摘要

第4章 醫藥品相關應用程式市場:製藥產業的行動應用程式、流通管道的目前活用狀況

  • 醫藥品相關應用程式的組合(產品結構)的規模與實際成果
  • 10種主要類別
  • 平台的偏好與地區性的擴展

第5章 應用程式組合比較

  • 應用程式組合的實際成果比較
  • 標的群組、主力地區、管理模式比較

第6章 大型製藥企業的應用程式簡介

  • Abbott/Abbvie
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Johnson&Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi Aventis

第7章 提高應用程式組合的實際成果的選項

第8章 醫藥品相關應用程式的目錄(各企業、各平台的一覽)

第9章 圖表一覽

目錄

The report analyzes the global app publishing activities of the 11 leading Pharma companies on Android and iOS devices. It provides a detailed picture of which app categories Pharma companies concentrate on, how many apps they have published, which user groups they target, how they organize their app business and how successful they are.

The report analyzes app publishing activities on three levels:

Level 1 - Pharma app publisher industry view: The first chapter provides an overview of how Pharma companies are making use of the app channel today and how this has changed over the last 12 months.

Level 2 - Comparison of Pharma app activities: In the second part of the report, the companies are being analyzed on a company level and compared against each other.

Level 3 - Pharma app publisher profiles: The third part provides detailed profiles of the companies' app activities. It also highlights the most successful apps for professional and private users (based on downloads).

Companies in scope:

  • Abbvie/Abbott
  • Astra Zeneca
  • Bayer HealthCare
  • Bristol-Myer Squibb
  • GlaxoSmithKline
  • Johnson&Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi-Aventis

Apps in scope:

All apps available in the Apple App Store and in Google Play, which have been published by one of the 11 pharma companies.

Regional scope:

Global

Target groups:

Anybody who is interested in mobile health, esp. pharma industry: app developer, pharma companies, investors, analysts, ...

Why read the report:

  • Analysis of 725 apps (iOS & Android) of the top pharma companies
  • Detailed benchmarking of the app activities of top pharma companies
  • Benchmarking includes the comparison of downloads, active users, target groups, app category, ...
  • Performance of the app portfolio of top 11 pharma companies, app publishing strategy, country focus, ...
  • Profiles of all pharma company app portfolios including top apps that target private and professional users
  • Based on the results of the benchmarking the report provides options for a better app portfolio performance for pharma apps

Table of Contents

1. Scope of the report

2. About research2guidance

3. Management summary

4. Pharma app market: How the Pharma industry uses the mobile app channel today

  • 4.1. The Pharma app portfolio size and performance
  • 4.2. The 10 main app categories of Pharma
  • 4.3. Platform preference and geographical reach of Pharma apps

5. App portfolio comparison

  • 5.1. Comparison of app portfolio performance
  • 5.2. Comparison of target groups, regional focus and governance models

6. Pharma Companies' App Profiles

  • 6.1. Abbott/Abbvie app profile
  • 6.2. AstraZeneca app profile
  • 6.3. Bayer Healthcare app profile
  • 6.4. Bristol-Myers Squibb app profile
  • 6.5. GlaxoSmithKline app profile
  • 6.6. Johnson&Johnson app profile
  • 6.7. Merck app profile
  • 6.8. Novartis app profile
  • 6.9. Pfizer app profile
  • 6.10. Roche app profile
  • 6.11. Sanofi Aventis app profile

7. Options for a better app portfolio performance

8. Pharma app catalogue (list of apps by company and platform)

9. List of figures

Back to Top